Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 18;12:2001–2014. doi: 10.2147/CMAR.S240695

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Tang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

LncRNA-ATB inhibits cisplatin-induced apoptosis. (A) Total apoptotic rates (including early and late apoptotic cells) of A549-ATB-OE, A549-ATB-sh, and A549 cells detected by flow cytometry, and (B) statistically analyzed. (C) Total apoptotic rates of A549-ATB-OE, A549-ATB-sh, and A549 cells treated with cisplatin (2 μg/mL) for 24 h, then detected by flow cytometry, and (D) quantified. (E) Apoptosis of H1975 cells overexpressing or silencing lncRNA-ATB, and (F) subsequent statistical analysis. (G) Effect of cisplatin (2 μg/mL) treatment on apoptosis of H1975 cells overexpressing or silencing lncRNA-ATB compared with control cells, and (H) subsequent quantification. Data are expressed as mean ± SD (n=3). *P<0.05; **P<0.01.